Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Deciphera Pharmaceuticals, Inc.

Home Clinical Trial Sponsors and OrganizationsDeciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc.

ACTIVE

200 Smith St, Waltham, Massachusetts, United Stateswww.deciphera.comPublic355 employeesEstablished: 2003-01-01

Also known as:

DCPH

Deciphera

Part of ONO PHARMACEUTICAL CO., LTD.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

15

3 active

Approvals

1

Total approvals

Agencies

1

Regulatory bodies

Founded

2003

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

8

53.3%

Phase 3

5

33.3%

Phase 2

2

13.3%

Trial Status Distribution

Active, not recruiting

3

20.0%

Recruiting

12

80.0%

Clinical Trials

Trials sponsored by this organization (15)

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

Jul 2026106 participants

Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

May 202678 participants

A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

Active, not recruiting

Jun 2024135 participants

This is a multicenter, randomized, Phase 3 study with vimseltinib or placebo in patients with Tenosynovial Giant Cell Tumor, consisting of 2 parts: Part 1 is double blinded and Part 2 is open label study

Active, not recruiting

May 2024123 participants

A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors

Active, not recruiting

Sep 2023223 participants

A clinical trial to learn how an investigational drug (vimseltinib) is absorbed, distributed, broken down, and removed from the body when given to people with liver problems

Jun 202348 participants

A study to learn the effects of ripretinib (study drug) on how midazolam behaves in the body of people with advanced gastrointestinal stromal tumor

May 202322 participants

A Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with Specific KIT Exon Mutations Who Were Previously Treated with Imatinib

Apr 202356 participants

Page 1 of 2

Approvals

Approvals by Agency

EMC

Electronic Medicines Compendium

1

Approvals

Recent Approvals

QINLOCK 50 mg tablets

News

Ono Pharmaceutical Expands AI-Driven Drug Discovery Into Neurology and Immunology Through Strategic Partnerships

- Ono Pharmaceutical expanded its collaboration with Congruence Therapeutics in March 2026 to include neurology and immunology drug discovery, extending beyond their previous oncology focus. - The company secured exclusive worldwide option rights over small molecule candidates developed through Congruence's Revenir computational platform in these new therapeutic areas. - Ono also partnered with Sinopia Biosciences on rare metabolic disorders while implementing operational changes including transferring Forxiga distribution back to AstraZeneca. - These strategic moves represent Ono's broader push to diversify its pipeline into areas of significant unmet medical need through AI-driven external collaborations.

On this page

Overview
Clinical Trials15
Approvals1
News1

Back to Organizations